ArticleNeoplasia (New York, N.Y.)2014
Mechanisms of buffer therapy resistance.
Article in Neoplasia (New York, N.Y.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 32 citations in OpenAlex.
- Transdermal bicarbonate buffer therapy increases intratumoral pH and elicits antitumor responses in bladder cancer.Frontiers in immunology · 2026Article
- Potentiation of immune checkpoint blockade with a pH-sensitizer as monitored in two pre-clinical tumor models with acidoCEST MRI.British journal of cancer · 2025Article
- Tumor microenvironment-responsive nanoformulations for breast cancer.Discover nano · 2024Review
- Clinical significance of acidic extracellular microenvironment modulated genes.Frontiers in oncology · 2024Article
- Tumor alkalization therapy: misconception or good therapeutics perspective? - the case of malignant ascites.Frontiers in oncology · 2024Article
- Immunomodulatory and pro-oncologic effects of ketamine and isoflurane anesthetics in a murine model.PloS one · 2023Article
- Cancer heterogeneity and metastasis: life at the edge.Clinical & experimental metastasis · 2022Review
- Back to basic: Trials and tribulations of alkalizing agents in cancer.Frontiers in oncology · 2022Article
- TME-Responsive Multistage Nanoplatform for siRNA Delivery and Effective Cancer Therapy.International journal of nanomedicine · 2021Review
- T-cells produce acidic niches in lymph nodes to suppress their own effector functions.Nature communications · 2020Article
- What is pH regulation, and why do cancer cells need it?Cancer metastasis reviews · 2019Review
- Article
- Tumor microenvironment-responsive nanoparticles for cancer theragnostic applications.Biomaterials research · 2018Review
- Metabolic Profiling of healthy and cancerous tissues in 2D and 3D.Scientific reports · 2017Article
- Concurrent Longitudinal EPR Monitoring of Tissue Oxygenation, Acidosis, and Reducing Capacity in Mouse Xenograft Tumor Models.Cell biochemistry and biophysics · 2017Article
- Gear Up for a pH Shift: A Responsive Iron(II) 2-Amino-6-picolyl-Appended Macrocyclic paraCEST Agent That Protonates at a Pendent Group.Inorganic chemistry · 2016Article
- Metabolic changes associated with tumor metastasis, part 1: tumor pH, glycolysis and the pentose phosphate pathway.Cellular and molecular life sciences : CMLS · 2016Review
- Inhibition of SW620 human colon cancer cells by upregulating miRNA-145.World journal of gastroenterology · 2016Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Many studies have shown that the acidity of solid tumors contributes to local invasion and metastasis. Oral pH buffers can specifically neutralize the acidic pH of tumors and reduce the incidence of local invasion and metastatic formation in multiple murine models. However, this effect is not universal as we have previously observed that metastasis is not inhibited by buffers in some tumor models, regardless of buffer used. B16-F10 (murine melanoma), LL/2 (murine lung) and HCT116 (human colon) tumors are resistant to treatment with lysine buffer therapy, whereas metastasis is potently inhibited by lysine buffers in MDA-MB-231 (human breast) and PC3M (human prostate) tumors. In the current work, we confirmed that sensitive cells utilized a pH-dependent mechanism for successful metastasis supported by a highly glycolytic phenotype that acidifies the local tumor microenvironment resulting in morphological changes. In contrast, buffer-resistant cell lines exhibited a pH-independent metastatic mechanism involving constitutive secretion of matrix degrading proteases without elevated glycolysis. These results have identified two distinct mechanisms of experimental metastasis, one of which is pH-dependent (buffer therapy sensitive cells) and one which is pH-independent (buffer therapy resistant cells). Further characterization of these models has potential for therapeutic benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.